Compare Bristol-Myers Squibb Co (BMY) vs VanEck Australian Floating Rate ETF (FLOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs VanEck Australian Floating Rate ETF — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while VanEck Australian Floating Rate ETF trades at $50.97. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while VanEck Australian Floating Rate ETF pays none. Which is the better fit depends on your goals.
| BMY | FLOT | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $62.37 | $51.09 |
52-Week Low | $42.60 | $50.72 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
FLOT trades at $50.98 with no recent price change. Technical indicators show a bullish moving average signal but bearish oscillators, with the 6-day RSI at 88.89 indicating overbought conditions. Recent dividends of $0.17 and $0.18 per share reflect income distribution. The ETF focuses on high-quality floating rate bonds, offering a 4.0% SEC yield, with potential upside if the Federal Reserve raises rates.
The outlook for FLOT is tied to interest rate movements, with potential gains from rising yields but risks from inflation and geopolitical tensions. Investors seeking short-term income may find value, though overbought technicals suggest caution. Credit quality remains high, but macroeconomic shifts could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →
